Sept 10 (Reuters) - Amylin Pharmaceuticals Inc:
* Amylin Pharmaceuticals and Biocon Limited enter a global development and
commercialization agreement for a novel peptide hybrid
* Says will provide expertise in peptide hormone development
* Says Biocon will leverage its experience in preclinical and clinical
development of diabetes products
* Says Biocon will utilize its expertise in recombinant microbial expression to
manufacture the compound
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Amylin Pharmaceuticals and Biocon Limited enter a global development and
commercialization agreement for a novel peptide hybrid
* Says will provide expertise in peptide hormone development
* Says Biocon will leverage its experience in preclinical and clinical
development of diabetes products
* Says Biocon will utilize its expertise in recombinant microbial expression to
manufacture the compound
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
